Pyxis Oncology (NASDAQ:PYXS) Price Target Lowered to $8.00 at Stifel Nicolaus

Pyxis Oncology (NASDAQ:PYXS) had its target price decreased by Stifel Nicolaus from $9.00 to $8.00 in a report released on Tuesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other research firms also recently commented on PYXS. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Stephens upped their target price on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Royal Bank Of Canada reduced their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Stock Down 4.2%

Shares of PYXS opened at $1.36 on Tuesday. The firm has a market cap of $84.67 million, a price-to-earnings ratio of -1.05 and a beta of 1.45. The business’s 50 day moving average is $1.52 and its two-hundred day moving average is $2.51. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter. On average, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its position in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after buying an additional 9,062 shares during the period. Dimensional Fund Advisors LP lifted its stake in Pyxis Oncology by 37.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after buying an additional 13,550 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after acquiring an additional 14,566 shares during the period. Velan Capital Investment Management LP grew its position in shares of Pyxis Oncology by 37.5% during the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock worth $122,000 after acquiring an additional 15,000 shares during the last quarter. Finally, LPL Financial LLC grew its position in shares of Pyxis Oncology by 150.7% during the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after acquiring an additional 21,100 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology News Summary

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: Quarterly results beat expectations — PYXS reported a loss per share of ($0.29) vs. consensus ($0.35) and generated $11.04M of revenue, showing better-than-expected near-term performance. This beats helped validate recent operations and may support longer-term valuation recovery. Earnings Press Release
• Positive Sentiment: Clinical progress — Pyxis completed target enrollment in the Phase 1 monotherapy dose‑expansion of MICVO (micvotabart pelidotin) in 2L+ R/M HNSCC in Q1 2026. Completion of enrollment advances a near‑term clinical catalyst (data/readout) that could materially move the stock if results are positive. Business Update
• Positive Sentiment: Analyst support remains — HC Wainwright reaffirmed a “buy” rating with a $7 price target, signaling ongoing institutional conviction in the story despite the low share price. HC Wainwright Note
• Neutral Sentiment: Short-interest reporting appears anomalous — multiple March filings list 0 shares short and 0.0 days-to-cover (with NaN changes), suggesting a likely data/reporting issue rather than a meaningful shift in short positioning. Treat this as unreliable until corrected by official exchanges.
• Negative Sentiment: Price target cut by a covering analyst — Stifel Nicolaus lowered its target from $9.00 to $8.00 (but kept a “buy” rating). A lower target, even with a buy rating, can pressure sentiment and weigh on the stock in the near term. Stifel Note

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.